#6 - Vertex Pharmaceuticals (NASDAQ:VRTX)
Weight-loss drugs are the darling of the biopharmaceutical sector. And if you’re looking for a blue-chip biopharma company to own for the next 10 years, you should consider Vertex Pharmaceuticals Inc. (NASDAQ: VRTX).
The company is the market share leader in cystic fibrosis (CF) treatments and expects to win approvals for its most recent CF drug in early January 2025. The once-daily drug, Vanzacaftor, will offer more convenient dosing and is projected to be more powerful than Trikafta, the company’s current blockbuster drug. Analysts also expect this to be the its most profitable drug.
In January, Vertex expects to get FDA approval for its non-opioid pain reliever, Suzetrigine. And the company continues to have one of the deepest pipelines in the industry. Keep in mind that approval for these drugs comes with patent protection for a number of years. That’s why analysts are forecasting earnings growth of over 3,000% in 2025—reason alone to buy the stock now and hold it for the next 10 years.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Read More - Current Price
- $408.26
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 18 Buy Ratings, 10 Hold Ratings, 3 Sell Ratings.
- Consensus Price Target
- $494.04 (21.0% Upside)
